Background: Hepatitis B virus and Hepatitis C virus infection is one of the\npublic health problems in Egypt. So we aimed to evaluate the efficacy of serum\nosteopontin as predictor of hepatic fibrosis regression and virological\nresponse in patients with chronic HBV or HCV infection. Methods: This\nstudy has been conducted on 74 HBeAg posoitive chronic HBV infection, 74\nchronic HCV infection and 74 healthy controls. HBV patients treated with\nEntecavir. HCV patients treated with sofosbuvir, daclatasvir with or without\nribavirin. One year post HBeAg seroconversion and 3 months after end of\nregular antiviral treatment for patients with chronic HBV and chronic HCV\ninfection respectively, hepatic condition was reevaluated. Results: 14.9% of\npatients with HBV, failed to achieve undetectable HBV DNA or HBeAg seroconversion\nand 2.7% of patients with HCV infection, failed to achieve SVR.\nIn chronic HBV, pretreatment high serum osteopontin predict failure of virological\nresponse and hepatic fibrosis regression at a cutoff > 115.5, with\n90.91% sensitivity, 82.54% specificity. Also high degree of liver stiffness predicts\nfailure of hepatic fibrosis regression at a cutoff > 8.7, with 81.8% sensitivity,\n73% specificity. Conclusions: In chronic HBV infection low osteopontin\npredicts good virological response and hepatic fibrosis regression. But it\nhas no role in predicting SVR or hepatic fibrosis regression in chronic HCV\ninfected patients.
Loading....